Apnimed, Inc., a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, announced on July 30, 2026 that it has priced its initial public offering at $16.00 per share for 12 million shares of common stock. The company said the offering is expected to generate gross proceeds of $192 million before taking into account underwriting discounts, commissions and offering-related expenses.
Alongside the primary offering, Apnimed has provided the underwriters with a 30-day option to buy up to an additional 1.8 million shares at the IPO price. The company said the common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol APMD on July 31, 2026, and the offering is anticipated to close on or about August 3, 2026, subject to customary closing conditions.
BofA Securities, Evercore ISI, Cantor and LifeSci Capital are serving as joint book-running managers for the transaction.
Apnimed develops oral therapies directed at sleep-related breathing disorders. Its lead candidate, AD109, is designed to improve oxygenation in people with obstructive sleep apnea and has completed two Phase 3 clinical trials, the company said. The New Drug Application for AD109 has been assigned a Prescription Drug User Fee Act goal date of February 28, 2027.
Context and implications
The IPO proceeds, before fees and expenses, are intended to provide the company with additional capital as it advances AD109 toward potential regulatory approval and commercialization. The allocation of funds was not detailed in the announcement.
The timing of the Nasdaq listing and the PDUFA goal date places the company on a near-term regulatory timeline: trading is set to begin at the end of July 2026 and the FDA action date for the AD109 NDA is in late February 2027.
Key points
- Apnimed priced 12 million shares at $16.00 per share, targeting $192 million in gross proceeds before expenses.
- Underwriters have a 30-day option to acquire up to 1.8 million additional shares at the IPO price.
- The company's lead candidate, AD109, has completed two Phase 3 trials and its NDA carries a PDUFA goal date of February 28, 2027; common stock is expected to trade as APMD on Nasdaq beginning July 31, 2026.
Risks and uncertainties
- The offering is subject to customary closing conditions, meaning the deal could be delayed or altered if those conditions are not met - a factor relevant to capital markets and investors in the biotech sector.
- The regulatory outcome for AD109 remains uncertain until the Prescription Drug User Fee Act goal date of February 28, 2027; the NDA review process will determine next steps for potential approval.
- The underwriters' option to purchase an additional 1.8 million shares could result in additional dilution if exercised, affecting shareholders and market supply of the company's stock.
Sectors impacted
- Healthcare and biotechnology - through Apnimed's development and regulatory pathway for a sleep-related breathing disorder therapy.
- Capital markets and equity investors - via the company's Nasdaq listing and the new supply of publicly traded shares.